Pluristem Takes Possession of and Moving Into New State-of-the-Art Manufacturing Facility

Pluristem Takes Possession of and Moving Into New State-of-the-Art
Manufacturing Facility

HAIFA, Israel, Jan. 30, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today that the company has taken possession of and is
moving into its new state-of-the-art GMP facility. The facility allows for the
production of mass quantities of PLacental eXpanded (PLX) cells that possess
the advantages of being grown utilizing Pluristem's patented 3D bioreactor

The new manufacturing facility will have the capability to produce different
PLX product candidates with the potential capacity of over 150,000 doses
annually. Additionally, if more indications are approved by regulators for
clinical trials, this new facility will enable us to supply PLX cells to
conduct these additional trials in parallel.

Zami Aberman, Chairman and CEO of Pluristem commented, "We are excited to
begin work in our new plant. With this new manufacturing facility, our company
is capable of combining the ideal characteristics of a supply source in the
placenta with a proprietary expansion technology that successfully addresses
the issues of reproducibility and cost to provide high numbers of reproducible
batches of the highest quality PLX cells. Our new facility allows increasing
the yield from one placenta to over ten times the yield from our previous
pilot facility, and puts us in a very strong competitive position compared to
traditional two-dimensional expansion technologies."

"Pluristem is developing PLX cell therapies that have shown safety and
potential efficacy for a range of indications in our pre-clinical and clinical
studies, and now we also have the technology and capabilities to make these
treatments, if fully developed and approved by the regulators, available on a
large-scale," Aberman added.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a leading developer
of placenta-based cell therapies. The Company's patented PLX (PLacental
eXpanded) cells are a drug delivery platform that releases a cocktail of
therapeutic proteins in response to a host of local and systemic inflammatory
and ischemic diseases. PLX cells are grown using the company's proprietary 3D
micro-environmental technology and are an "off-the-shelf" product that
requires no tissue matching prior to administration. Pluristem is focusing on
the development of PLX cells administered locally to potentially treat
systemic diseases and potentially obviating the need to use the intravenous

Pluristem has a strong patent and patent applications portfolio, company-owned
GMP certified manufacturing and research facilities, strategic relationships
with major research institutions and a seasoned management team. For more
information visit, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available at

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, we are using forward-looking
statements when we discuss our new manufacturing facility, its production
capacity, its capability to produce different PLX products and increased yield
from one placenta that it allows, when we discuss our competitive advantage,
or when we discuss our capabilities to make cell treatments, if fully
developed and approved by the regulators, available on a large-scale. These
forward-looking statements are based on the current expectations of the
management of Pluristem only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. The following factors, among
others, could cause actual results to differ materially from those described
in the forward-looking statements: changes in technology and market
requirements; we may encounter delays or obstacles in launching and/or
successfully completing our clinical trials; our products may not be approved
by regulatory agencies, our technology may not be validated as we progress
further and our methods may not be accepted by the scientific community; we
may be unable to retain or attract key employees whose knowledge is essential
to the development of our products; unforeseen scientific difficulties may
develop with our process; our products may wind up being more expensive than
we anticipate; results in the laboratory may not translate to equally good
results in real surgical settings; results of preclinical studies may not
correlate with the results of human clinical trials; our patents may not be
sufficient; our products may harm recipients; changes in legislation;
inability to timely develop and introduce new technologies, products and
applications; loss of market share and pressure on pricing resulting from
competition, which could cause the actual results or performance of Pluristem
to differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Pluristem undertakes no
obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem, reference is
made to Pluristem's reports filed from time to time with the Securities and
Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         Daya Lettvin
         Investor & Media Relations Director

Pluristem Therapeutics Inc. Logo
Press spacebar to pause and continue. Press esc to stop.